Lipitor

Pfizer Sells Capsugel: Will More Asset Sales Follow?

On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

How to Protect Yourself From Counterfeit Drugs Online

Even if the fake drug you buy online doesn't kill or even hurt you, the transaction itself can reveal your financial and medical information to questionable (at best) characters. Protecting yourself starts with understanding the dangers. Plus: Here are some helpful tips.

Pfizer's Potential Arthritis Drug Works in Late-Stage Trial

Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant's report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.

Pfizer Buys King Pharma for $3.6 Billion

With King in its fold, Pfizer -- which makes Lyrica and Celebrex -- believes it can build an industry-leading portfolio of pain relievers. Among King's most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.

WHO Approves Pfizer's Pediatric Pneumococcus Vaccine

The World Health Organization has granted prequalification to Pfizer's Prevnar 13 pediatric vaccine, which protects against an array of pneumococcal diseases, the world's leading cause of vaccine-preventable death in children under 5. Pfizer's shares rose more than 1% Monday.

Pfizer Earnings Rise 9%, Topping Estimates

Pfizer (PFE) reported Tuesday that its second-quarter profit increased 9%, handily beating analyst expectations, as it further cut costs and revenue jumped sharply due to its acquisition of Wyeth last October.

AstraZeneca Stock Jumps After Court Ruling on Crestor

AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.

Pfizer's Pipeline Looks Primed to Deliver

The stock of the world's largest drugmaker has been a laggard lately. But that could be soon changing if analysts who are pointing to a solid lineup of new products are right. They think the giant can easily offset the patent loss for Lipitor.

Inside Wall Street: A Cholesterol Drug Could Be Big

If promising early results of its cholesterol-busting drug RVX-208 get supported in larger clinical trials, it could put this young company on the map in a big way. A partnership with a major drugmaker is a very strong possibility.

Wider Approval for Crestor Brings Out Cynics

Earlier this week, AstraZeneca's widely used cholesterol-lowering drug Crestor was approved by the U.S. Food and Drug Administration for use in people with normal cholesterol to prevent heart attacks and strokes. The approval could lead to a much bigger market for Crestor, but has also led to a number of critics questioning the decision.

Crestor Backed by FDA for Patients With Normal Cholesterol

AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.